Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D, Portron A, Backholer Z, Lausecker B, Kawashima K. Schwab D, et al. Among authors: portron a. Clin Pharmacokinet. 2013 Jun;52(6):463-73. doi: 10.1007/s40262-013-0051-z. Clin Pharmacokinet. 2013. PMID: 23494983 Clinical Trial.
Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study.
Schwab D, Sturm C, Portron A, Fuerst-Recktenwald S, Hainzl D, Jordan P, Stewart WC, Tepedino ME, DuBiner H. Schwab D, et al. Among authors: portron a. BMJ Open Ophthalmol. 2017 Jun 29;1(1):e000063. doi: 10.1136/bmjophth-2016-000063. eCollection 2017. BMJ Open Ophthalmol. 2017. PMID: 29354707 Free PMC article.
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
Schmitt C, Portron A, Jadidi S, Sarkar N, DiMarchi R. Schmitt C, et al. Among authors: portron a. Diabetes Obes Metab. 2017 Oct;19(10):1436-1445. doi: 10.1111/dom.13024. Epub 2017 Jul 20. Diabetes Obes Metab. 2017. PMID: 28730694 Clinical Trial.
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V. Pipe SW, et al. Among authors: portron a. Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16. Lancet Haematol. 2019. PMID: 31003963 Clinical Trial.
Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma.
Yamamoto Y, Sanwald Ducray P, Björnsson M, Smart K, Grimsey P, Vatakuti S, Portron A, Massonnet B, Norris DA, Silber Baumann HE. Yamamoto Y, et al. Among authors: portron a. CPT Pharmacometrics Syst Pharmacol. 2023 Sep;12(9):1213-1226. doi: 10.1002/psp4.13001. Epub 2023 Jun 13. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37221972 Free PMC article.
Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Yoneyama K, Schmitt C, Portron A, Kiialainen A, Kotani N, Jaminion F, Retout S, Adamkewicz JI. Yoneyama K, et al. Among authors: portron a. Expert Rev Clin Pharmacol. 2023 Jul-Dec;16(9):775-790. doi: 10.1080/17512433.2023.2243213. Epub 2023 Aug 21. Expert Rev Clin Pharmacol. 2023. PMID: 37529848 Review.
16 results